Top

Current Hepatology Reports

Published in:

01-06-2018 | Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Ethnic and Racial Differences in Autoimmune Liver Diseases

Authors: Arnaldo Freire, Cynthia Levy

Published in: Current Hepatology Reports | Issue 2/2018

Abstract

Purpose of the review

To discuss the ethnic and racial disparities observed in patients with autoimmune liver diseases, with special focus on epidemiology, patterns of inheritance, clinical presentation, and outcomes.

Recent findings

Black, Hispanics, and Asians with autoimmune hepatitis appear to have more aggressive clinical features, poorer initial response to standard therapy, and higher rates of complications including hepatocellular carcinoma, with worse survival than their White counterparts. African American and Hispanic patients with primary biliary cholangitis have more advanced disease at presentation and Hispanics appear to have lower rates of biochemical response to UDCA compared to non-Hispanics. African American patients with PSC are significantly younger at presentation and appear to have more aggressive liver disease when compared to European Americans.

Summary

The clinical presentation and outcomes of autoimmune liver diseases vary by ethnicity and race, with significant disparities reported in recent years. The goal of this review is to make clinicians aware of these differences to facilitate diagnosis and management of autoimmune liver diseases and eventually improve outcomes across various races and ethnicities.

Jepsen P, Grønbæk L, Vilstrup H. Worldwide incidence of autoimmune liver disease. Dig Dis. 2015;33(2):2–12.CrossRefPubMed

Dyson JK, Webb G, Hirschfield GM, Lohse A, Beuers U, Lindor K, et al. Unmet clinical need in autoimmune liver diseases. J Hepatol. 2015;62(1):208–18.CrossRefPubMed

Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology. 2008;47(3):1058–66.CrossRefPubMed

Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis—update 2015. J Hepatol. 2015;62(1 Suppl):S100–11.CrossRefPubMed

Liberal R, Longhi MS, Mieli-Vergani G, Vergani D. Pathogenesis of autoimmune hepatitis. Best Pract Res Clin Gastroenterol. 2011;25(6):653–64.CrossRefPubMed

Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–213.CrossRefPubMed

Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354(1):54–66.CrossRefPubMed

Liberal R, Krawitt EL, Vierling JM, Manns MP, Mieli-Vergani G, Vergani D. Cutting edge issues in autoimmune hepatitis. J Autoimmun. 2016;75:6–19.CrossRefPubMed

Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(1):169–76.CrossRefPubMed

10.

Hurlburt KJ, Mcmahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska natives. Am J Gastroenterol. 2002;97(9):2402–7.CrossRefPubMed

11.

Ngu JH, Bechly K, Chapman BA, Burt MJ, Barclay ML, Gearry RB, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol. 2010;25(10):1681–6.CrossRefPubMed

12.

Gerven NMV, Verwer BJ, Witte BI, Erpecum KJV, Buuren HRV, Maijers I, et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands. Scand J Gastroenterol. 2014;49(10):1245–54.CrossRefPubMed

13.

Delgado J-S, Vodonos A, Malnick S, Kriger O, Wilkof-Segev R, Delgado B, et al. Autoimmune hepatitis in southern Israel: a multicenter study of 15 years. J Dig Dis. 2013;14(11):611–8.PubMed

14.

Kim BH, Choi HY, Ki M, Kim K-A, Jang ES, Jeong S-H. Population-based prevalence, incidence, and disease burden of autoimmune hepatitis in South Korea. PLoS One. 2017;12(8):e0182391.CrossRefPubMedPubMedCentral

15.

Czaja A. Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients. Semin Liver Dis. 2009;29(03):315–30.CrossRefPubMed

16.

Deneau M, Jensen MK, Holmen J, Williams MS, Book LS, Guthery SL. Primary sclerosing cholangitis, autoimmune hepatitis, and overlap in Utah children: epidemiology and natural history. Hepatology. 2013;58(4):1392–400.CrossRefPubMed

17.

Boer YSD, Gerven NMV, Zwiers A, Verwer BJ, Hoek BV, Erpecum KJV, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology. 2014;147(2):443–52.

18.

Qiu D-K, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. J Gastroenterol Hepatol. 2003;18(1):63–7.CrossRefPubMed

19.

Yoshizawa K, Ota M, Katsuyama Y, Ichijo T, Matsumoto A, Tanaka E, et al. Genetic analysis of the HLA region of Japanese patients with type 1 autoimmune hepatitis. J Hepatol. 2005;42(4):578–84.CrossRefPubMed

20.

Hassan N, Siddiqui AR, Abbas Z, Hassan SM, Soomro GB, Mubarak M, et al. Clinical profile and HLA typing of autoimmune hepatitis from Pakistan. Hepat Mon. 2013;13(12):e13598.CrossRefPubMedPubMedCentral

21.

Zolfino T. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut. 2002;50(5):713–7.CrossRefPubMedPubMedCentral

22.

Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol. 2001;96(12):3390–4.CrossRefPubMed

23.

Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007;46(6):1828–35.CrossRefPubMed

24.

Wong RJ, Gish R, Frederick T, Bzowej N, Frenette C. The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol. 2012;46:155–61.CrossRefPubMed

25.

Kim TI, Kagihara JE, Tsai NCS, Roytman MM. Autoimmune Hepatitis in Hawai’i. Hawai’i J Med Public Health. 2015;74:270–4.

26.

Selmi C, Bowlus C, Gershwin M, Coppel R. Primary biliary cirrhosis. Lancet. 2011;377:1600–9.CrossRefPubMed

27.

Arndtz K, Hirschfield GM. The pathogenesis of autoimmune liver disease. Dig Dis. 2016;34(4):327–33.CrossRefPubMed

28.

• Hirschfield GM, Beuers U, Corpechot C, Invernizzi P, Jones D, Marzioni M, et al. EASL Clinical Practice Guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145–72. Most recent clinical practice guidelines that summarize the evidence for the importance of a structured, life-long, and individualized approach to the care of patients with PBC. CrossRef

29.

Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012;56(5):1181–8.CrossRefPubMed

30.

Kim W, Lindor KD, Locke G, Therneau TM, Homburger HA, Batts KP, et al. Epidemiology and natural history of primary biliary cirrhosis in a U.S. community. Gastroenterology. 2000;119(6):1631–6.CrossRefPubMed

31.

Kanth R, Shrestha RB, Rai I, Vanwormer JJ, Roy PK. Incidence of primary biliary cholangitis in a rural Midwestern population. Clin Med Res. 2017;15:13–8.CrossRefPubMedPubMedCentral

32.

•• Lu M, Li J, Haller IV, Romanelli RJ, Vanwormer JJ, Rodriguez CV, et al. Factors associated with prevalence and treatment of primary biliary cholangitis in United States Health Systems. Clin Gastroenterol Hepatol. 2017. https://doi.org/10.1016/j.cgh.2017.10.018. Recent electronic health record-based study identified large cohort of patients with PBC receiving routine clinical care. Significant differences in PBC prevalence and treatment by sex, race, and age were found including the fact that African Americans are less likely to receive treatment for PBC compared to Whites.

34.

Delgado J-S, Vodonos A, Delgado B, Jotkowitz A, Rosenthal A, Fich A, et al. Primary biliary cirrhosis in southern Israel: a 20 year follow up study. Eur J Intern Med. 2012;23(8):e193–8.CrossRefPubMed

35.

Boonstra K, Kunst AE, Stadhouders PH, Tuynman HA, Poen AC, Nieuwkerk KMJV, et al. Rising incidence and prevalence of primary biliary cirrhosis: a large population-based study. Liver Int. 2014;34(6):e31–8.CrossRefPubMed

36.

Rautiainen H, Salomaa V, Niemelä S, Karvonen A-L, Nurmi H, Isoniemi H, et al. Prevalence and incidence of primary biliary cirrhosis are increasing in Finland. Scand J Gastroenterol. 2007;42(11):1347–53.CrossRefPubMed

37.

Selmi C, Mayo MJ, Bach N, Ishibashi H, Invernizzi P, Gish RG, et al. Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology. 2004;127(2):485–92.CrossRefPubMed

38.

Yanagisawa M, Takagi H, Takahashi H, Uehara M, Otsuka T, Yuasa K, et al. Familial clustering and genetic background of primary biliary cirrhosis in Japan. Dig Dis Sci. 2009;55:2651–8.CrossRefPubMed

39.

Abu-Mouch S, Selmi C, Benson GD, Kenny TP, Invernizzi P, Zuin M, et al. Geographic clusters of primary biliary cirrhosis. Clin Dev Immunol. 2003;10:127–31.CrossRefPubMedPubMedCentral

40.

Bach B, Schaffner F. Familial primary biliary cirrhosis. J Hepatol. 1994;20:698–701.CrossRefPubMed

41.

Floreani A, Naccarato R, Chiaramonte M. Prevalence of familial disease in primary biliary cirrhosis in Italy. J Hepatol. 1997;26:737–8.CrossRefPubMed

42.

Webb G, Hirschfield G. Using GWAS to identify genetic predisposition in hepatic autoimmunity. J Autoimmun. 2016;66:25–39.CrossRefPubMed

43.

Marzorati S, Lleo A, Carbone M, Gershwin ME, Invernizzi P. The epigenetics of PBC: the link between genetic susceptibility and environment. Clin Res Hepatol Gastroenterol. 2016;40:650–9.CrossRefPubMed

44.

Peters MG, Bisceglie AM, Kowdley KV, Flye NL, Luketic VA, Munoz SJ, et al. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology. 2007;46(3):769–75.CrossRefPubMedPubMedCentral

45.

• Levy C, Naik J, Giordano C, Mandalia A, Obrien C, Bhamidimarri KR, et al. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics. Clin Gastroenterol Hepatol. 2014;12:1398–405. Cross-sectional study reporting an increased prevalence of overlap syndrome of PBC-AIH, reduced response to UDCA treatment, and more frequent complications of portal hypertension among Hispanics with PBC compared to the non-Hispanic patients. CrossRefPubMed

46.

•• Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2016;65:321–9. Recent large international cohort that robustly demonstrated that a 12-month biochemical non-response is associated with increased future risk of developing HCC in PBC. CrossRefPubMed

47.

Hirschfield GM, Karlsen TH, Lindor KD, Adams DH. Primary sclerosing cholangitis. Lancet. 2013;382:1587–99.CrossRefPubMed

48.

Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology. 2010;51:660–78.CrossRefPubMed

49.

Boonstra K, Weersma RK, Erpecum KJ, Rauws EA, Spanier BM, Poen AC, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58(6):2045–55.CrossRefPubMed

50.

Molodecky NA, Kareemi H, Parab R, Barkema HW, Quan H, Myers RP, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53:1590–9.CrossRefPubMed

51.

Lindkvist BCB, Valle MBD, Gullberg B, Björnsson E. Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology. 2010;52:571–7.CrossRefPubMed

52.

Bambha K, Kim WR, Torgerson H, Benson J, Loftus E, Talwalkar J. Incidence, clinical spectrum and outcomes of primary sclerosing cholangitis in a U.S. community. Gastroenterology. 2003;125:1364–9.CrossRefPubMed

53.

Toy E, Balasubramanian S, Selmi C, Li C-S, Bowlus CL. The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population. BMC Gastroenterol. 2011;11:1–7.CrossRef

54.

Kelly P, Patchett S, Mccloskey D, Alstead E, Farthing M, Fairclough P. Sclerosing cholangitis, race and sex. Gut. 1997;41(5):688–9.CrossRefPubMedPubMedCentral

55.

Buchel OC, Bosch FJ, van Janse Rensburg J, Bezuidenhout E, de Vries CS, van Zyl JH, et al. Primary sclerosing cholangitis, Crohn’s disease and HLA-B27 in black South African women. Acta Gastroenterol Belg. 2012;75(4):454–7.PubMed

56.

• Goldberg D, Levy C, Yimam K, Gordon S, Forman L, Verna E, et al. Primary sclerosing cholangitis is not rare among Blacks in a Multicenter North American Consortium. Clin Gastroenterol Hepatol. 2017. https://doi.org/10.1016/j.cgh.2017.10.028. Data from multicenter North American consortium which suggests that incidence of PSC among Black patients is higher than previously described.

57.

Folseraas T, Melum E, Franke A, Karlsen TH. Genetics in primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2011;25:713–26.CrossRefPubMed

58.

Spurkland A, Saarinen S, Boberg KM, Mitchell S, Broome U, Caballeria L, et al. HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens. 1999;53(5):459–69.CrossRefPubMed

59.

Neri TM, Cavestro GM, Seghini P, Zanelli PF, Zanetti A, Savi M, et al. Novel association of HLA- haplotypes with primary sclerosing cholangitis (PSC) in a southern European population. Dig Liver Dis. 2003;35(8):571–6.CrossRefPubMed

60.

Bittencourt PL, Palacios SA, Cancado EL, Carrilho FJ, Porta G, Kalil J, et al. Susceptibility to primary sclerosing cholangitis in Brazil is associated with HLA-DRB1*13 but not with tumour necrosis factor alpha -308 promoter polymorphism. Gut. 2002;51(4):609–10.CrossRefPubMedPubMedCentral

61.

Bowlus CL, Li C-S, Karlsen TH, Lie BA, Selmi C. Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transpl. 2010;16:1324–30.CrossRefPubMedPubMedCentral

Title: Ethnic and Racial Differences in Autoimmune Liver Diseases
Authors: Arnaldo Freire
Cynthia Levy
Publication date: 01-06-2018
Publisher: Springer US
Published in: Current Hepatology Reports / Issue 2/2018
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-018-0399-5

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Ethnic and Racial Differences in Autoimmune Liver Diseases

Abstract

Purpose of the review

Recent findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of the review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 2/2018

Expanding Capacity to Treat Hepatitis C: Overcoming Barriers and New Innovations

Nutritional Assessment and Management for Hospitalized Patients with Cirrhosis

The Newest Direct-Acting Antiviral Agents: the Final Chapter in DAA Development

Strategies for the Elimination of Hepatitis C Virus Infection as a Public Health Threat in the United States

Treatment of DAA-Experienced Patients with Chronic Hepatitis C

Therapeutics for Pruritus in Cholestatic Liver Disease: Many Treatments but Few Cures

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page